vs

Side-by-side financial comparison of HighPeak Energy, Inc. (HPK) and Ultragenyx Pharmaceutical Inc. (RARE). Click either name above to swap in a different company.

HighPeak Energy, Inc. is the larger business by last-quarter revenue ($216.6M vs $207.3M, roughly 1.0× Ultragenyx Pharmaceutical Inc.). HighPeak Energy, Inc. runs the higher net margin — -11.6% vs -62.0%, a 50.4% gap on every dollar of revenue. On growth, Ultragenyx Pharmaceutical Inc. posted the faster year-over-year revenue change (25.9% vs -23.3%). Over the past eight quarters, Ultragenyx Pharmaceutical Inc.'s revenue compounded faster (38.0% CAGR vs -13.2%).

Duke Energy Corporation is an American electric power and natural gas holding company headquartered in Charlotte, North Carolina. The company serves over 7 million customers in the eastern United States. In 2024 it ranked as the 141st largest company in the United States – its highest-ever placement on the Fortune 500 list.

Ultragenyx Pharmaceutical Inc. is an American biopharmaceutical company involved in the research and development of novel products for treatment of rare and ultra-rare genetic diseases for which there are typically no approved treatments and high unmet medical need. The company works with multiple drug modalities including biologics, small molecule, gene therapies, and ASO and mRNAs in the disease categories of bone, endocrine, metabolic, muscle and CNS diseases.

HPK vs RARE — Head-to-Head

Bigger by revenue
HPK
HPK
1.0× larger
HPK
$216.6M
$207.3M
RARE
Growing faster (revenue YoY)
RARE
RARE
+49.2% gap
RARE
25.9%
-23.3%
HPK
Higher net margin
HPK
HPK
50.4% more per $
HPK
-11.6%
-62.0%
RARE
Faster 2-yr revenue CAGR
RARE
RARE
Annualised
RARE
38.0%
-13.2%
HPK

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
HPK
HPK
RARE
RARE
Revenue
$216.6M
$207.3M
Net Profit
$-25.2M
$-128.6M
Gross Margin
Operating Margin
-7.6%
-54.7%
Net Margin
-11.6%
-62.0%
Revenue YoY
-23.3%
25.9%
Net Profit YoY
-380.7%
3.5%
EPS (diluted)
$-0.16
$-1.28

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
HPK
HPK
RARE
RARE
Q4 25
$216.6M
$207.3M
Q3 25
$188.9M
$159.9M
Q2 25
$200.4M
$166.5M
Q1 25
$257.4M
$139.3M
Q4 24
$282.6M
$164.6M
Q3 24
$271.6M
$139.5M
Q2 24
$275.3M
$147.0M
Q1 24
$287.8M
$108.8M
Net Profit
HPK
HPK
RARE
RARE
Q4 25
$-25.2M
$-128.6M
Q3 25
$-18.3M
$-180.4M
Q2 25
$26.2M
$-115.0M
Q1 25
$36.3M
$-151.1M
Q4 24
$9.0M
$-133.2M
Q3 24
$49.9M
$-133.5M
Q2 24
$29.7M
$-131.6M
Q1 24
$6.4M
$-170.7M
Operating Margin
HPK
HPK
RARE
RARE
Q4 25
-7.6%
-54.7%
Q3 25
17.3%
-106.9%
Q2 25
21.7%
-64.8%
Q1 25
35.1%
-102.6%
Q4 24
26.1%
-74.3%
Q3 24
27.0%
-94.6%
Q2 24
31.7%
-79.1%
Q1 24
35.8%
-151.9%
Net Margin
HPK
HPK
RARE
RARE
Q4 25
-11.6%
-62.0%
Q3 25
-9.7%
-112.8%
Q2 25
13.1%
-69.0%
Q1 25
14.1%
-108.5%
Q4 24
3.2%
-80.9%
Q3 24
18.4%
-95.7%
Q2 24
10.8%
-89.5%
Q1 24
2.2%
-156.8%
EPS (diluted)
HPK
HPK
RARE
RARE
Q4 25
$-0.16
$-1.28
Q3 25
$-0.15
$-1.81
Q2 25
$0.19
$-1.17
Q1 25
$0.26
$-1.57
Q4 24
$0.06
$-1.34
Q3 24
$0.35
$-1.40
Q2 24
$0.21
$-1.52
Q1 24
$0.05
$-2.03

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
HPK
HPK
RARE
RARE
Cash + ST InvestmentsLiquidity on hand
$162.1M
$421.0M
Total DebtLower is stronger
$1.2B
Stockholders' EquityBook value
$1.6B
$-80.0M
Total Assets
$3.2B
$1.5B
Debt / EquityLower = less leverage
0.75×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
HPK
HPK
RARE
RARE
Q4 25
$162.1M
$421.0M
Q3 25
$164.9M
$202.5M
Q2 25
$21.9M
$176.3M
Q1 25
$51.6M
$127.1M
Q4 24
$86.6M
$174.0M
Q3 24
$135.6M
$150.6M
Q2 24
$157.9M
$480.7M
Q1 24
$173.4M
$112.3M
Total Debt
HPK
HPK
RARE
RARE
Q4 25
$1.2B
Q3 25
$1.2B
Q2 25
$1.0B
Q1 25
$1.0B
Q4 24
$1.0B
Q3 24
$1.1B
Q2 24
$1.1B
Q1 24
$1.1B
Stockholders' Equity
HPK
HPK
RARE
RARE
Q4 25
$1.6B
$-80.0M
Q3 25
$1.6B
$9.2M
Q2 25
$1.7B
$151.3M
Q1 25
$1.6B
$144.2M
Q4 24
$1.6B
$255.0M
Q3 24
$1.6B
$346.8M
Q2 24
$1.6B
$432.4M
Q1 24
$1.5B
$140.3M
Total Assets
HPK
HPK
RARE
RARE
Q4 25
$3.2B
$1.5B
Q3 25
$3.2B
$1.2B
Q2 25
$3.1B
$1.3B
Q1 25
$3.1B
$1.3B
Q4 24
$3.1B
$1.5B
Q3 24
$3.1B
$1.5B
Q2 24
$3.1B
$1.6B
Q1 24
$3.1B
$1.3B
Debt / Equity
HPK
HPK
RARE
RARE
Q4 25
0.75×
Q3 25
0.73×
Q2 25
0.62×
Q1 25
0.63×
Q4 24
0.65×
Q3 24
0.67×
Q2 24
0.70×
Q1 24
0.73×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
HPK
HPK
RARE
RARE
Operating Cash FlowLast quarter
$93.1M
$-99.8M
Free Cash FlowOCF − Capex
$-100.8M
FCF MarginFCF / Revenue
-48.6%
Capex IntensityCapex / Revenue
0.5%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-472.0M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
HPK
HPK
RARE
RARE
Q4 25
$93.1M
$-99.8M
Q3 25
$120.2M
$-91.4M
Q2 25
$141.2M
$-108.3M
Q1 25
$157.1M
$-166.5M
Q4 24
$139.5M
$-79.3M
Q3 24
$177.1M
$-67.0M
Q2 24
$202.3M
$-77.0M
Q1 24
$171.4M
$-190.7M
Free Cash Flow
HPK
HPK
RARE
RARE
Q4 25
$-100.8M
Q3 25
$-92.7M
Q2 25
$-110.7M
Q1 25
$-167.8M
Q4 24
$-79.5M
Q3 24
$-68.6M
Q2 24
$-79.0M
Q1 24
$-193.9M
FCF Margin
HPK
HPK
RARE
RARE
Q4 25
-48.6%
Q3 25
-58.0%
Q2 25
-66.5%
Q1 25
-120.5%
Q4 24
-48.3%
Q3 24
-49.2%
Q2 24
-53.7%
Q1 24
-178.2%
Capex Intensity
HPK
HPK
RARE
RARE
Q4 25
0.5%
Q3 25
0.8%
Q2 25
1.5%
Q1 25
1.0%
Q4 24
0.1%
Q3 24
1.2%
Q2 24
1.4%
Q1 24
3.0%
Cash Conversion
HPK
HPK
RARE
RARE
Q4 25
Q3 25
Q2 25
5.39×
Q1 25
4.32×
Q4 24
15.53×
Q3 24
3.55×
Q2 24
6.81×
Q1 24
26.63×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

HPK
HPK

Crude Oil Sales$152.1M70%
Natural Gas And NGL Sales$60.8M28%

RARE
RARE

Royalty$105.6M51%
Products$101.7M49%

Related Comparisons